This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chien, S. C.
Right arrow Articles by Nayak, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chien, S. C.
Right arrow Articles by Nayak, R. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1997, 1562-1565, Vol 41, No. 7
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects

SC Chien, AT Chow, J Natarajan, RR Williams, FA Wong, MC Rogge and RK Nayak
The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.

The influence of age and gender on the pharmacokinetics of levofloxacin in healthy subjects receiving a single oral 500-mg dose of levofloxacin was investigated in this parallel design study. Six young males (aged 18 to 40 years), six elderly males (aged > or = 65 years), six young females (aged 18 to 40 years), and six elderly females (aged > or = 65 years) were enrolled and completed the study. The study reveals that the bioavailability (rate and extent) of levofloxacin was not affected by either age or gender. In both age (young and elderly) and gender (male and female) groups of subjects, peak concentrations in plasma were reached at approximately 1.5 h after dosing; renal clearance of levofloxacin accounted for approximately 77% of total body clearance, and approximately 76% of the administered dose was recovered unchanged in urine over the 36 h of collection. The apparent differences in the calculated pharmacokinetic parameters for levofloxacin between the age groups (young versus elderly) and between the gender groups (males versus females) could be explained by differences in renal function among the subjects. A single dose of 500 mg of levofloxacin administered orally to both young and old, male and female healthy subjects was found to be safe and well tolerated. As the differences in levofloxacin kinetics between the young and the elderly or the males and the females are limited and are mainly related to the renal function of the subjects, dose adjustment based on age or gender alone is not necessary.


This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Overholser, B. R., Kays, M. B., Forrest, A., Sowinski, K. M. (2004). Sex-Related Differences in the Pharmacokinetics of Oral Ciprofloxacin. J Clin Pharmacol 44: 1012-1022 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Lubenko, I. Yu., Arzamastsev, A. P., Portnoy, Y. A., Zinner, S. H. (2004). ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 54: 178-186 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2004). Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci. Antimicrob. Agents Chemother. 48: 86-92 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., Zinner, S. H. (2003). In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1604-1613 [Abstract] [Full Text]  
  • Furlanut, M., Brollo, L., Lugatti, E., Di Qual, E., Dolcet, F., Talmassons, G., Pea, F. (2003). Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51: 101-106 [Abstract] [Full Text]  
  • Firsov, A. A., Zinner, S. H., Vostrov, S. N., Portnoy, Y. A., Lubenko, I. Yu. (2002). AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 50: 533-539 [Abstract] [Full Text]  
  • Reid, J., Marciniuk, D., Peloquin, C. A., Hoeppner, V. (2002). Pharmacokinetics of Antituberculosis Medications Delivered via Percutaneous Gastrojejunostomy Tube. Chest 121: 281-284 [Abstract] [Full Text]  
  • Baden, L. R., Horowitz, G., Jacoby, H., Eliopoulos, G. M. (2001). Quinolones and False-Positive Urine Screening for Opiates by Immunoassay Technology. JAMA 286: 3115-3119 [Abstract] [Full Text]  
  • Villani, P., Viale, P., Signorini, L., Cadeo, B., Marchetti, F., Villani, A., Fiocchi, C., Regazzi, M. B., Carosi, G. (2001). Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy. Antimicrob. Agents Chemother. 45: 2160-2162 [Abstract] [Full Text]  
  • Geerdes-Fenge, H. F., Wiedersich, A., Wagner, S., Lehr, K.-H., Koeppe, P., Lode, H. (2000). Levofloxacin Pharmacokinetics and Serum Bactericidal Activities against Five Enterobacterial Species. Antimicrob. Agents Chemother. 44: 3478-3480 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Yu., Vostrov, S. N., Kononenko, O. V., Zinner, S. H., Portnoy, Y. A. (2000). Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother 46: 725-732 [Abstract] [Full Text]  
  • Lubasch, A., Keller, I., Borner, K., Koeppe, P., Lode, H. (2000). Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers. Antimicrob. Agents Chemother. 44: 2600-2603 [Abstract] [Full Text]  
  • Entenza, J. M., Caldelari, I., Glauser, M. P., Moreillon, P. (1999). Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. J Antimicrob Chemother 44: 775-786 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»